Amendment: SEC Form SC 13G/A filed by Travere Therapeutics Inc.
$TVTX
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/21/2024 | $9.00 → $27.00 | Equal Weight → Overweight | Wells Fargo |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 9/9/2024 | $25.00 | Neutral → Buy | Guggenheim |
| 3/27/2024 | Buy → Neutral | Guggenheim | |
| 12/5/2023 | $7.00 → $10.00 | Neutral → Buy | Citigroup |
| 11/20/2023 | $7.00 | Neutral | Citigroup |
| 9/22/2023 | $24.00 → $8.00 | Overweight → Equal Weight | Wells Fargo |
| 9/21/2023 | Outperform → Mkt Perform | William Blair |
4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
FILSPARI® (sparsentan) received full FDA approval as the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN Type C meeting scheduled with FDA to discuss potential sNDA submission for FILSPARI in FSGS sNDA requesting modification of liver monitoring for FILSPARI submitted to FDA Net product sales of FILSPARI totaled $35.6 million for the third quarter of 2024; 505 new PSFs received in the period Total revenue for the third quarter of 2024 was $62.9 million, including net product sales of $61.0 million SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today reported its third quarter 2024 financial result
SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report third quarter 2024 financial results on Thursday, October 31, 2024, before the open of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 8:30 a.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for li
SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)
SC 13G - Travere Therapeutics, Inc. (0001438533) (Subject)
SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)
Wells Fargo upgraded Travere Therapeutics from Equal Weight to Overweight and set a new price target of $27.00 from $9.00 previously
Scotiabank initiated coverage of Travere Therapeutics with a rating of Sector Outperform
Guggenheim upgraded Travere Therapeutics from Neutral to Buy and set a new price target of $25.00
8-K - Travere Therapeutics, Inc. (0001438533) (Filer)
424B5 - Travere Therapeutics, Inc. (0001438533) (Filer)
424B5 - Travere Therapeutics, Inc. (0001438533) (Filer)
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 24,400 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan ("2018 Plan") but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years, with 25% of the
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the completion of its previously announced underwritten public offering of 8,984,375 shares of its common stock at a price to the public of $16.00 per share, including 1,171,875 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares. All of the shares were sold by Travere. Including the option exercise, the aggregate gross proceeds from the offering were approximately $143.8 million, before deducting the underwriting discounts and commissions and offering expenses. Jefferies and Leerink Partners acted as the joint book-running managers for t
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the pricing of an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of $16.00 per share. All of the shares are being sold by Travere. The gross proceeds from the offering are expected to be $125.0 million, before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close on November 12, 2024, subject to customary closing conditions. In addition, Travere has granted the underwriters for the offering a 30-day option to purchase up to an additional 1,171,875 shares of its common stock at the public
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Below are some instances of options activity happening in the Health Care sector: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume AMGN CALL SWEEP BEARISH 07/19/24 $320.00 $27.4K 2.5K 277 LLY CALL TRADE BEARISH 08/16
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. Shares of NVIDIA Corporation (NASDAQ:NVDA) rose during Tuesday's session. Keybanc analyst John Vinh maintained NVIDIA with an Overweight and raised the price target from $130 to $180. NVIDIA shares gained 3.5% to $132.65 on Tuesday. Here are some other big stocks recording gains in today’s session. Kymera Therapeutics, Inc. (NASDAQ:KYMR) shares rose 21.7% to $38.91. Jumia Technologies AG (NYSE:JMIA) shares surged 20.7% to $10.22 after Benchmark initiated coverage on the stock with a Buy rating and $14 price target. Arlo Technologies, Inc. (NYSE:ARLO) shares gained 14.5% to $15.80 afte
HC Wainwright & Co. analyst Ed Arce reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $19 price target.
Meissa Vaccines ("Meissa"), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced the appointment of Frank Glavin as Chief Executive Officer, bringing more than 20 years of biotech and pharma experience across the biotech value chain from early-stage research through to commercial planning and business development. Martin Moore, Ph.D., cofounder of Meissa, will serve as the Company's Chief Scientific Officer. "I am excited to welcome Frank to the Meissa leadership team," said Dr. Moore. "We are at an important stage in Meissa's growth, and Frank brings extensive, complementary experience in commercial planning, business developm
Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022. A gifted physician-scientist and leading oncologist, Dr. Baynes is among the most experienced – and most successful – clinical development leaders in the biopharmaceutical industry. Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice President and Chief Medical Officer in J
SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the appointment of Jula Inrig, M.D., as chief medical officer, effective immediately. Dr. Inrig brings to Travere more than 15 years of expertise in medical oversight, drug development, clinical trial planning and execution and global regulatory engagement. Dr. Inrig joins the Company as it prepares for accelerated approval submissions of sparsentan for IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) in 2022, as well as the continued advancement of its pegtibatinase program in classical homocystinuria (HCU). "We are excited to welcome Jula to the Travere Therapeutics